MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

Search

Cellectar Biosciences Inc

Gesloten

0.23 -8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.22

Max

0.25

Belangrijke statistieken

By Trading Economics

Werknemers

11

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+300% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.2M

16M

Vorige openingsprijs

8.23

Vorige sluitingsprijs

0.23

Cellectar Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2024, 18:44 UTC

Belangrijke Marktbewegers

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Peer Vergelijking

Prijswijziging

Cellectar Biosciences Inc Prognose

Koersdoel

By TipRanks

300% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1 USD  300%

Hoogste 1 USD

Laagste 1 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cellectar Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Financieel

$

Over Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.